Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
复制标题
DOI：
10.1126/science.289.5483.1352
复制
发表时间：
2000-08-25
期刊：
影响因子：
56.9
通讯作者：
Remaut, E
中科院分区：
文献类型：
--
作者：
Steidler, L;Hans, W;Remaut, E
细胞因子白细胞介素-10（IL-10）在临床试验中已显示出治疗炎性鲍尔病（IBD）的前景。使用两种小鼠模型，我们表明IL-10的治疗剂量可以通过局部递送经基因工程改造以分泌细胞因子的细菌来减少，灌胃给予分泌IL-10的乳酸乳球菌可使葡聚糖硫酸钠治疗的小鼠结肠炎减少50%，并可预防IL-10治疗的小鼠结肠炎发作。10只（-/-）小鼠。这种方法可能会导致更好的方法，成本效益和长期管理IBD的人类。
The cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of inflammatory bower disease (IBD), Using two mouse models, we show that the therapeutic dose of IL-10 can be reduced by Localized delivery of a bacterium genetically engineered to secrete the cytokine, Intragastric administration of IL-10-secreting Lactococcus lactis caused a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the onset of colitis in IL-10(-/-) mice. This approach may Lead to better methods for cost-effective and Long-term management of IBD in humans.